PT - JOURNAL ARTICLE ED - , TI - ▼Relvar Ellipta for asthma AID - 10.1136/dtb.2014.8.0273 DP - 2014 Aug 01 TA - Drug and Therapeutics Bulletin PG - 93--96 VI - 52 IP - 8 4099 - http://dtb.bmj.com/content/52/8/93.short 4100 - http://dtb.bmj.com/content/52/8/93.full SO - Drug Ther Bull2014 Aug 01; 52 AB - ▼Relvar Ellipta (GSK) is a dry powder inhaler that contains a corticosteroid (fluticasone furoate) and a long-acting beta2 agonist (vilanterol trifenatate). It is licensed for once-daily use as maintenance therapy for chronic obstructive pulmonary disease (COPD) and asthma. In a previous article we considered its use in the management of COPD.1 Here we review the evidence for Relvar Ellipta in the treatment of patients with asthma.